|
|
|
04.11.26 - 15:33
|
Viele Trends, eine Aktie: AKTIONÄR-Tipp Bruker hebt ab (Der Aktionaer)
|
|
|
Die Aktie von Bruker fliegt hierzulande immer etwas unter dem Radar vieler Marktteilnehmer. Dabei agiert das Unternehmen im wichtigen Bereich der instrumentellen Analytik und ist damit mit seinen Lösungen in vielen Branchen unverzichtbar. Nach eher enttäuschenden Quartalszahlen zuletzt können sich die Ergebnisse zum vergangenen dritten Quartal sehen lassen....
|
|
|
|
|
04.11.26 - 13:03
|
Bruker Reports Third Quarter 2026 Financial Results (Business Wire)
|
|
|
Q3-26 revenue of $874.0 million, up 1.6% yoy; up 0.7% organically
Q3-26 non-GAAP operating margin of 16.3%, up 400 bps yoy
Q3-26 GAAP diluted Loss Per Share of $(0.81); Non-GAAP diluted EPS of $0.56, up 24.4% yoy
Reconfirming prior FY2026 organic revenue growth and non-GAAP EPS guidance
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and nine months ended September 30, 2026.
Frank H. Laukien, Bruker's President and CEO, commented: “Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successful drug development and useful AI frontier models. Together with strong growth-drivers in infectious disease diagnostics, and in deep-tech and semiconductor metrology, we are poised for growth acceleration.”
He cont...
|
|
|
20.10.26 - 22:06
|
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast (Business Wire)
|
|
|
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends.
To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins.
Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker's Third Quarter 2026 Earnings Conference Call.”
Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.08.26 - 13:06
|
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development (Business Wire)
|
|
|
MIMETAS' unique organ-on-a-chip and human tissue models complement Bruker's multiomics, NMR, spatial biology and preclinical imaging solutionsLEIDEN, The Netherlands--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker's post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems.
MIMETAS develops scalable organ-on-a-chip platforms and human tissue models that allow researchers to study disease mechanisms and compound responses in perfused, biologically relevant systems. Its OrganoPlate® platform combines a standard microtiter-plate format with membrane-free microfluidic tissue cultures, supporting imagi...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
